- Home
- MYGN vs PDM Comparison
MYGN vs PDM Comparison
Compare MYGN & PDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- PDM
- Stock Information
- Founded
- MYGN 1991
- PDM 1997
- Country
- MYGN United States
- PDM United States
- Employees
- MYGN N/A
- PDM N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PDM Building operators
- Sector
- MYGN Health Care
- PDM Real Estate
- Exchange
- MYGN Nasdaq
- PDM Nasdaq
- Market Cap
- MYGN 1.2B
- PDM 1.1B
- IPO Year
- MYGN 1995
- PDM N/A
- Fundamental
- Price
- MYGN $14.18
- PDM $7.07
- Analyst Decision
- MYGN Hold
- PDM Buy
- Analyst Count
- MYGN 13
- PDM 3
- Target Price
- MYGN $22.54
- PDM $11.00
- AVG Volume (30 Days)
- MYGN 1.2M
- PDM 842.4K
- Earning Date
- MYGN 02-24-2025
- PDM 02-13-2025
- Dividend Yield
- MYGN N/A
- PDM 7.11%
- EPS Growth
- MYGN N/A
- PDM N/A
- EPS
- MYGN N/A
- PDM N/A
- Revenue
- MYGN $823,600,000.00
- PDM $570,324,000.00
- Revenue This Year
- MYGN $13.60
- PDM N/A
- Revenue Next Year
- MYGN $3.25
- PDM N/A
- P/E Ratio
- MYGN N/A
- PDM N/A
- Revenue Growth
- MYGN 12.15
- PDM N/A
- 52 Week Low
- MYGN $12.04
- PDM $5.93
- 52 Week High
- MYGN $29.30
- PDM $11.12
- Technical
- Relative Strength Index (RSI)
- MYGN 55.82
- PDM 22.63
- Support Level
- MYGN $14.13
- PDM $7.16
- Resistance Level
- MYGN $15.47
- PDM $7.48
- Average True Range (ATR)
- MYGN 0.72
- PDM 0.26
- MACD
- MYGN 0.27
- PDM -0.12
- Stochastic Oscillator
- MYGN 61.38
- PDM 3.28
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About PDM Piedmont Office Realty Trust Inc.
Piedmont Office Realty Trust Inc is a real estate investment trust engaged in the acquisition, development, and management of commercial real estate properties throughout the U.S. The company's real estate portfolio is mainly composed of office properties located in the majority of American metropolitan areas. Piedmont derives majority of its revenue in the form of rental income from tenants in mid- to long-term lease agreements. The vast majority of the company's revenue comes from the leasing of its assets in Washington D.C., New York City, Chicago, Atlanta, Minneapolis, Dallas, and Boston. Piedmont's large customers in terms of rental revenue are U.S. Government entities, business services companies, and financial institutions.